Daniel Goldstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniel Goldstein has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dhawal Priyadarshi
Biomedical Genetics Section, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
1 shared publication - Gyungah Jun
Biomedical Genetics Section Department of Medicine Boston University Chobanian and Avedisian School of Medicine Boston Massachusetts USA
1 shared publication - Kwangsik Nho
Department of Radiology and Imaging Sciences and the Indiana Alzheimer's Disease Research Center Indiana University School of Medicine Indianapolis Indiana USA
1 shared publication - Lindsay A. Farrer
Bioinformatics Program, Boston University, Boston, USA
1 shared publication - Nathan Sahelijo
Biomedical Genetics Section, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
1 shared publication - Rebecca Panitch
Biomedical Genetics Section, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
1 shared publication
Latest Publications
- Open Access
- 10 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 2885
Blood–Brain Network-Based Polygenic Risk Scores Reveal Biomarker Signatures and the Progression of Alzheimer’s Disease
Background: Polygenic risk scores for Alzheimer’s disease (AD), organized by gene networks shared between the blood and brain, may provide insights into underlying disease mechanisms common to both tissues. Methods: We derived a blood–brain network-based polygenic risk score (nbPRS) from AD-associated genetic variants for three blood-brain networks, selected by the preservation of blood and brain gene co-expression networks, and AD association. Participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI, n = 1109), Framingham Heart Study (FHS, n = 8310), the Religious Orders Study Memory Aging Project (ROSMAP, n = 1215), and Mount Sinai Brain Bank (MSBB, n = 323) were stratified into low- and high-nbPRS subgroups, then profiled using longitudinal and cross-sectional data. We compared the conversion from normal cognition to AD between nbPRS subgroups. Genes differentially expressed among low- and high-nbPRS individuals were profiled with classical neuropathological markers and we investigated potential biologically relevant pathways for the genes significantly expressed in high-risk individuals. Results: Individuals with high nbPRS in three AD-associated networks (M2, M6, M14) demonstrated significant impairment in executive function and memory performance, whereas high-risk individuals in networks M2 and M14 had significantly reduced hippocampal volume. We observed high-risk individuals in M2 and M14 developed AD at twice the rate of low-risk individuals in these networks. HLA genes were differentially expressed with transcriptome-wide significance among low- and high-nbPRS individuals in M14 and associated with neuroinflammatory and tau pathology. Conclusions: Polygenic risk scores derived from blood and brain networks can differentiate individuals with a high risk of AD conversion.
- 10 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 2885
Open AccessBlood–Brain Network-Based Polygenic Risk Scores Reveal Biomarker Signatures and the Progression of Alzheimer’s Disease
Background: Polygenic risk scores for Alzheimer’s disease (AD), organized by gene networks shared between the blood and brain, may provide insights into underlying disease mechanisms common to both tissues. Methods: We derived a blood–brain network-based polygenic risk score (nbPRS) from AD-associated genetic variants for three blood-brain networks, selected by the preservation of blood and brain gene co-expression networks, and AD association. Participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI, n = 1109), Framingham Heart Study (FHS, n = 8310), the Religious Orders Study Memory Aging Project (ROSMAP, n = 1215), and Mount Sinai Brain Bank (MSBB, n = 323) were stratified into low- and high-nbPRS subgroups, then profiled using longitudinal and cross-sectional data. We compared the conversion from normal cognition to AD between nbPRS subgroups. Genes differentially expressed among low- and high-nbPRS individuals were profiled with classical neuropathological markers and we investigated potential biologically relevant pathways for the genes significantly expressed in high-risk individuals. Results: Individuals with high nbPRS in three AD-associated networks (M2, M6, M14) demonstrated significant impairment in executive function and memory performance, whereas high-risk individuals in networks M2 and M14 had significantly reduced hippocampal volume. We observed high-risk individuals in M2 and M14 developed AD at twice the rate of low-risk individuals in these networks. HLA genes were differentially expressed with transcriptome-wide significance among low- and high-nbPRS individuals in M14 and associated with neuroinflammatory and tau pathology. Conclusions: Polygenic risk scores derived from blood and brain networks can differentiate individuals with a high risk of AD conversion.